ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1278

The Arthritis Severity and Joint Damage Locus Cia25/Pia42 Is a New Genetic Regulator of the Invasive Properties of Synovial Fibroblasts

Max Brenner1,2, Teresina Laragione1,2 and Percio Gulko1,2, 1Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 2Molecular Medicine, Hosftra North Shore-LIJ School of Medicine, Manhasset, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Animal models, Autoimmunity, genetics, inflammatory arthritis and synovial cells, synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is a chronic and commonly disabling disease with a prevalence of 1% world-wide. Disease remission is rarely achieved with current treatments and little is known about the genes that control disease severity and joint damage. We have identified the arthritis severity and joint damage regulatory quantitative trait locus, Cia25/Pia42 on rat chromosome 12, in an intercross between MHC-identical arthritis-susceptible DA and arthritis-resistant ACI rats. Cia25/Pia42 regulates collagen-induced arthritis (CIA) and pristane-induced arthritis (PIA), two established models of RA. Cia25/Pia42 regulates the synovial expression of IL-6, IL-1β, MMP-3 and other key mediators of arthritis pathogenesis. In this study we aimed at reducing the chromosomal interval containing the gene accounting for Cia25/Pia42, and to study its effect in fibroblast-like synoviocytes (FLS).

Methods: We used genotype-guided breeding to generate twelve different DA.ACI(Cia25/Pia42) subcongenic strains. These new strains were studied in the homozygous state in PIA, and their FLS studied in an in vitroinvasion assay through Matrigel known to correlate with histologic and radiographic damage.

Results: Based on the analyses of the arthritis severity and protection in the twelve new subcongenics we were able to reduce the gene-containing interval from 23Mb to 1.7Mb. The new and reduced interval contains 34 genes. FLS from congenics had an 80% reduction in invasion, compared with DA (p=0.02).

Conclusion: We have significantly reduced the Cia25/Pia42 interval towards positional cloning, and identified evidence suggesting that at least part of its effect is mediated via FLS function and invasion. The discovery of the Cia25-Pia42 gene has the potential to generate a new target for therapy in arthritis, and a new prognostic biomarker for RA.


Disclosure:

M. Brenner,
None;

T. Laragione,
None;

P. Gulko,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-arthritis-severity-and-joint-damage-locus-cia25pia42-is-a-new-genetic-regulator-of-the-invasive-properties-of-synovial-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology